DOCSLIB.ORG

Full Schedule ILANIT 20Th-23Rd of February 2017

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Full Schedule ILANIT 20Th-23Rd of February 2017 Full Schedule ILANIT 20th-23rd of February 2017 MONDAY, FEBRUARY 20, 2017 10:45-15:30 Registration and Refreshments - Dan hotel 15:30-16:00 Opening Ceremony -Herods hotel – Pavilion 16:00-17:00 PL1: PLENARY LECTURE: Regulation of microRNA Herods hotel - Pavilion Narry Kim is a Professor at Seoul National University and a founding director of RNA Research Center at Institute for Basic Science. Kim received her Ph.D. in 1998 from Oxford University on virology, and studied mRNA surveillance as postdoc at the University of Pennsylvania. Her group at SNU has been investigating how microRNAs are made and regulated, and what RNAs and RNA-binding proteins do to control cell fates. Kim received L’Oreal-UNESCO Women in Science (2008) and the Ho-Am Prize in Medicine (2009), and was elected as Foreign Associates of National Academy of Science and of European Molecular Biology Organization. Sponsored by: I-CORE Gene Regulation in Human Complex Disease 17:30-18:30 PL2: PLENARY LECTURE: Being at the Base of the Food Chain May Not Be So Bad After All Herods hotel - Pavilion Prof. Ian T. Baldwin received an AB from Dartmouth College in 1981, his PhD from Cornell University in 1989, rose through the academic ranks at the State University of New York at Buffalo and in 1996 became the founding director of the Max Planck Institute for Chemical Ecology in Jena, Germany, where he heads the Department of Molecular Ecology. He is a member of the US National Academy of Sciences, European Molecular Biology Organization (EMBO), Nationale Akademie der Wissenschaften Leopoldina, Berlin Brandenburgische Akademie der Wissenschaften, Wissenschaftskolleg Berlin, and has published 430 peer-reviewed papers and one book on the Induced defenses of plants. Sponsored by: I-CORE Plant Adaptation to Changing Environment 19:00-23:00 Opening Reception Dinner - Dan hotel Pool Area 2 TUESDAY, FEBRUARY 21, 2017 07:30-08:30 EBT1: Early bird session of Eldan Electronic Instruments Co.Ltd., Herods hotel - Kings hall A Session participants will be enrolled in a lottery having the chance to win a tablet. 08:30 CRISPR Guide RNA Libraries for Functional Genomics Screening: Do You Know What’s in Your Library? Dr. Carsten Carstens Agilent Technologies, Eldan Electronic Instruments Co.Ltd. Screening of CRISPR libraries, either as a knock-out or as a CRISPR A/I approach, has become a very powerful tool for functional genomics approaches to gene function discovery. The quality of the library screen is strongly dependent on the quality of the input library. Based on Agilent’s capability to synthesize up to 2.44 x 105 high quality defined DNA oligomers of 230 nt in length in a single reaction, we have developed novel chemistries, and novel, overlap-based cloning method and workflows necessary for generating high quality, low-bias plasmid libraries. The session will present the procedures and tools required to generate highest quality plasmid libraries from complex oligomer pools. 08:00 Integrated Tools for Sensitive NGS Analysis of ccfDNA Katja Schreiter Ph.D., Market Development Manager BRC & NGS Commercial Partners EMEA QIAGEN, Eldan Electronic Instruments Co.Ltd. Next generation sequencing analysis of free circulating DNA from plasma has quickly been adopted for cancer testing as well as for noninvasive prenatal testing (NIPT). For cancer patients, this method enables the noninvasive diagnosis of actionable mutants to select a personalized anti-tumor therapy and could be used to monitor molecular changes upon cancer treatment or during tumor progression. The concentration of free circulating DNA in liquid biopsies usually is very low, which makes it very important to apply optimized protocols for cfDNA extraction as well as NGS DNA library construction to successfully establish robust test systems. In this scientific talk, we will introduce new technical solutions for Ion Torrent as well as Illumina sequencing platforms that combine optimized cfDNA isolation, highly advanced library construction, unbiased library amplification and integrated data analysis to sensitively and reliably analyze cfDNA samples. 3 TUESDAY, FEBRUARY 21, 2017 07:30-08:30 EBT2: Early Bird session of Zotal Herods hotel - Kings hall B Session participants will be enrolled in a lottery having the chance to win a tablet. 07:30 RNA-Seq as an Efficient Tool for Gene Expression Profiling QuantSeq: High Multiplexing, Sensitivity, and Reproducibility with Lowest Costs and Efforts Birgit Steinmetz Product Manager at Lexogen-Zotal With the discontinuation of microarray systems and the rapid development of NGS technologies, and declining sequencing costs, attention is now on RNA-Seq as the method-of- choice for gene expression (GEX) profiling. Lexogen’s QuantSeq 3’ mRNA-Seq system offers a comprehensive and highly affordable solution for whole transcriptome GEX analyses: With a price from USD 19.80 per library prep and sequencing costs from USD 5.00 per sample, easy handling, and an all-in-one express protocol that is suitable for high throughput screening QuantSeq enables exceptionally precise and cost-effective gene expression experiments. Since only 1 fragment per transcript is generated, FPKM calculations are unnecessary, and a recommended read depth of 2-5 million short, single-end reads per sample is sufficient for expression profiling of eukaryotic transcriptomes. 08:00 Cisbio Help You Make Your Immunoassay a Success: from Research to Drug Development Dr. Ullrike Esslinger Scientific Consultant at Cisbio Bio Assay. Cisbio-Zotal Cisbio Bioassays develops and markets products and technologies used in life sciences and diagnostics. With over 30 years' expertise in assay conception, the company has become the leader in the field of TR-FRET immunoassays with HTRF®, its proprietary technology. Based on this highly robust and reliable format, Cisbio Bioassays offers first class assays and services for drug discovery researchers, from basic research to all steps of new lead identification and optimization. Our kits are already adopted for different researches in CNS, Oncology, Metabolism and Cardiology, but not only. It can also help in your drug development process like HTS or leads optimization. Our scientists are ready to help you to develop custom kit that will perfectly fit your needs. in this session we will share insights about our technology and how it will help you to be successful with your immunoassay. 4 TUESDAY, FEBRUARY 21, 2017 07:30-08:30 EBT3: Early bird session of 3D-Biology – NanoString Technologies Dan hotel - Blue hall A Session participants will be enrolled in a lottery having the chance to win a tablet. 07:30 The Power of 3D-Biology™: Simultaneous Detection of DNA, RNA, and Proteins Rudy van Eijsden, Ph.D. Field Application Specialist, nanoString Technologies The digital NanoString nCounter® technology enables you to count up to 800 molecules per sample in a highly multiplexed fashion. To meet the need for multi-analyte profiling in for example tumor biology, NanoString Technologies has expanded its single-molecule digital barcoding system to recognize DNA, RNA, fusions, proteins and phospho-proteins simultaneously from the same sample with its 3D Biology™ technology. Detection of DNA (e.g. SNVs), RNA, or proteins alone can provide significant information, but when data from multiple experiments are merged the integrated results can lead to novel hypotheses or more solid conclusions. Examples will be presented how 3D Biology™ can add extreme value to your research. Less sample, more data, easy to analyze! TUESDAY, FEBRUARY 21, 2017 08:00-08:30 EBT4: Early bird session of Mercury Dan hotel - Blue hall B Session participants will be enrolled in a lottery having the chance to win a tablet. 08:00 Biomarkers Quantification using Multiplex Technology Improving Result Accuracy and Sensitivity Quantify a full panel of biomarkers is one assay! Dr. Ben Levi Mercury Milliplex® Multiplexing is highly validated and sensitive technique, which enables you to achieve reproducible data while saving precious time. Milliplex® is a lead multiplexing kit, utilizing Luminex 5 technology, employing a simple protocol. Analysis of numerous factors simultaneously made possible within a small volume of biological sample, in a cost-effective manner. TUESDAY, FEBRUARY 21, 2017 09:00-10:45 TUE9: Motors and Machines in Cells Herods hotel - Kings hall A Joint session between Israel Society for Biochemistry and Molecular Biology & Israeli Forum for Cytoskeleton and Motility Chair: Alexander Bershadsky, Weizmann Institute of Science Chair: Leah Gheber, Ben Gurion University 09:00 New Role for the Actin-Based Motor Myosin 19 in Mitochondria Localization Arnon Henn, Boris I. Shneyer, Marko Ušaj Faculty of Biology, Technion - Israel Institute of Technology, Israel 09:20 New Insights into the Role and Regulation of Myosin II in Cytokinesis Shoshana Ravid, Daniel Ronen, Ari Babkoff, Einav Kfir-Cohen, Areen Mghndaf, Adam Gobi Department of Biochemistry and Molecular Biology, The Hebrew University of Jerusalem, Israel 09:40 Microtubule Stability and Motor Proteins Function Can Be Regulated by Neurotrophic Factors Eran Perlson Physiology and Pharmacology, Tel Aviv University, Israel 10:00 Cellular Mechanosensing of Extracellular Matrix Rigidity by Contractile Units Controlled by Receptor Tyrosine Kinases Haguy Wolfenson Department of Genetics and Developmental Biology, Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Israel 10:15 Chlamydomonas Ciliary Tubulin: from Dynamic instability To Length Control Ron Orbach,
Load more

Recommended publications
  • NIBN Establishing Why the NIBN NIBN Prof
    REPORT Highlight on NIBN Establishing Why the NIBN NIBN Prof. Varda Shoshan-Barmatz Prof. Irun R. Cohen, MD, Director Deputy Director Prof. Sir Aaron Klug, OM, FRS Many have asked how Israel might succeed The National Institute for Biotechnology in in achieving greater returns in intellectual the Negev (NIBN) is proud to publish this Chair of the International NIBN REPORT. Advisory Committee property and biotechnology products for a The purpose of the NIBN REPORT is to given investment in basic research in the summarize the progress and achievements It is now five years since we first made life sciences. Or to be more specific, why of the NIBN, which is at the spearhead of the approach to the Government for do I think the NIBN will be more effective the University's efforts to promote excellence funding a National Institute of than previous efforts in launching successful in research. The NIBN, made possible biotechnology. I shall answer that question Biotechnology in the Negev at BGU. through the magnanimous support and by summarizing the problems inherent in vision of Dr. h.c. Edgar de Picciotto of The basis was to be the Institute of Applied the relationship between university research Switzerland, brings together scientists from Biosciences which had been built and and biotechnology to clarify the rationale different disciplines with medical personnel funded with the generous support of of the NIBN model and its implementation. and professional consultants to create a Dr. h.c. Edgar de Picciotto of Geneva. front-line interdisciplinary institute focusing University and Biotechnology on biotechnology. It was his vision that this Institute could in Conflict of Interest Revolutions come in stages, and we have and would form the nucleus of a future now advanced from the first stages of National Center for Biotechnology.
    [Show full text]
  • Strategies for Improving Influenza Immunization Rates Among Hard-To-Reach Populations
    Journal of Urban Health: Bulletin of the New York Academy of Medicine, Vol. 84, No. 4 doi:10.1007/s11524-007-9197-z * 2007 The New York Academy of Medicine For permissions, please e-mail: [email protected] Advance Access publication Strategies for Improving Influenza Immunization Rates among Hard-to-Reach Populations David Vlahov, Micaela H. Coady, Danielle C. Ompad, and Sandro Galea ABSTRACT Whereas considerable attention has been devoted to achieving high levels of influenza immunization, the importance of this issue is magnified by concern over pandemic influenza. Most recommendations for vaccine administration address high risk groups such as the elderly and those with chronic diseases, but coverage for hard- to-reach (HTR) populations has had less attention. HTR populations include minorities but also include other primarily urban groups such as undocumented immigrants, substance users, the homeless, and homebound elderly. Obstacles to the provision of immunization to HTR populations are present at the patient, provider, and structural levels. Strategies at the individual level for increasing immunization coverage include community-based educational campaigns to improve attitudes and increase motivation for receiving vaccine; at the provider level, education of providers to encourage immunizations, improving patient–provider interactions, broadening the provider base to include additional nurses and pharmacists, and adoption of standing orders for immunization administration; and at the structural level, promoting
    [Show full text]
  • OPTIONS X Programme
    Options X for the Control of Influenza | WELCOME MESSAGES BREAKTHROUGH INFLUENZA VACCINES TAKE LARGE DOSES OF INNOVATION Protecting people from the ever-changing threat of influenza takes unwavering commitment. That’s why we’re dedicated to developing advanced technologies and vaccines that can fight influenza as it evolves. We’re with you. ON THE FRONT LINETM BREAKTHROUGH INFLUENZA VACCINES TAKE LARGE DOSES OF INNOVATION CONTENT OPTIONS X SUPPORTERS ------------------- 4 OPTIONS X EXHIBITORS & COMMITTEES ------------------- 5 AWARD INFORMATION ------------------- 6 WELCOME MESSAGES ------------------- 7 SCHEDULE AT A GLANCE ------------------- 10 CONFERENCE INFORMATION ------------------- 11 SOCIAL PROGRAMME ------------------- 14 ABOUT SINGAPORE ------------------- 15 SUNTEC FLOORPLAN ------------------- 16 SCIENTIFIC COMMUNICATIONS ------------------- 17 PROGRAMME ------------------- 19 SPEAKERS ------------------- 31 SPONSORED SYMPOSIA ------------------- 39 ORAL PRESENTATION LISTINGS ------------------- 42 POSTER PRESENTATION LISTINGS ------------------- 51 ABSTRACTS POSTER DISPLAY LISTINGS ------------------- 54 SPONSOR AND EXHIBITOR LISTINGS ------------------- 80 EXHIBITION FLOORPLAN ------------------- 83 Protecting people from the ever-changing threat of NOTE ------------------- 84 influenza takes unwavering commitment. That’s why we’re dedicated to developing advanced technologies and vaccines that can fight influenza as it evolves. We’re with you. ON THE FRONT LINETM Options X for the Control of Influenza | OPTIONS X SUPPORTERS
    [Show full text]
  • V21 MTG 0033 List of Particip
    THE FIRST WHO INTEGRATED MEETING ON DEVELOPMENT AND CLINICAL TRIALS OF INFLUENZA VACCINES THAT INDUCE BROADLY PROTECTIVE AND LONG-LASTING IMMUNE RESPONSES Baptist University, Hong Kong 24 – 26 January 2013 LIST OF PARTICIPANTS Dr Akira Ainai, Emeritus Member, National Institute of Infectious Diseases, Tokyo, Japan Dr Christopher Ambrose, Senior Director, Medical Affairs, MedImmune, Gaithersburg, United States of America Professor Filippo Ansaldi, Health Sciences, University of Genoa and Hygiene Unit, Genoa, Italy Dr Robert L. Atmar, Associate Professor, Department of Medicine and Molecular Virology & Microbiology, Baylor College of Medicine, Houston, United States of America Dr Emma Ball, CSL Limited A.C.N., Parkville, Victoria, Australia Dr Pamuk Bilsel, FluGen Inc., Madison, United States of America Mr Albert Chan, President, Hong Kong Baptist University, Hong Kong, China Dr Paul Chan, Department of Microbiology, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China Dr Marta Coehlo Nunes, Respiratory and Meningeal Pathogens Research Unit, Wits University, Johannesburg, South Africa Dr Ben Cowling, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China Dr Manon Cox, President and CEO, Protein Sciences Corporation, Meridien, United States of America Professor Rebecca Cox, Influenza Centre, The Gade Institute, University of Bergen, Bergen, 5021 Norway Dr Giuseppe Del Giudice, Global Head Translation Medicine, Novartis Vaccines and Diagnostics S.p.A, Divisione Biologici
    [Show full text]
  • Jurnalul Ozanei ➧
    ❙ ➧ ➧ Jurnalul Ozanei ➧ ➧❙ Luana Zosmer ➥ TEXT ➥ ❐ ✔ archives ´equivalences la prose du monde ✖ 2004 1 ❙ ➧ ➧ present edition: Adrian Rezus¸ (ed.) c 2004 Luana Zosmer [Hana Fratu] (Hertzliah, Israel) [text] c 2004 Luana Zosmer [Hana Fratu] (Hertzliah, Israel) [graphics] ➧ • Egon Schiele [cover i Wally mit roter Bluse (1913)] c 2004 equivalences´ [pdfLATEX – hyperscreen] ➧❙ This electronic edition is a non-profit publication produced by pdfTEX 14.h & ➥ created by LATEX 2ε with hyperref & hyperscreen ➥ pdfTEX14.h c 2001 Han` Theˆ´ Thanh` LATEX 2ε c 1993–2001 the LATEX3 project team et al. hyperref c 1995–2001 Sebastian Rahtz ❐ hyperscreen c 2001-2002 Adrian Rezus¸[based on pdfscreen] pdfscreen c 1999–2001 C. V. Radhakrishnan ✔ typeset by romanianTEX c 1994–2001 Adrian Rezus¸ printed in the netherlands – December 15, 2004 ✖ 2 ❙ ➧ ➧ ➧ Luana Zosmer ➧❙ Jurnalul Ozanei ➥ ➥ ❐ ✔ Hert¸lia 2004 ✖ 3 ❙ ➧ ➧ ➧ ➧❙ ➥ ➥ ❐ ✔ ✖ 4 1 Americanii-s ˆınerect¸ie, ˆı¸siˆınchipuie c-au descoperit apa cu zah˘ar,sex ¸simarele ora¸s,caca de bivol (nu ˆınt¸eleg expresia; caca de cˆaine“ ar fi mai potrivit; dup˘acum se ” ¸stie c˘acatul de cˆaine-inimica, nu face decˆat s˘aput˘a);acu’ s˘anu ˆınt¸eleget¸i c˘aserialul ❙ ➧ ˘alanu-i mi¸stode tot; este, da’ chestia cu muierile dezl˘ant¸uite e veche de cˆandbunic˘a- mea-¸sif˘aceaochi dulci cu locotenentul – ea din balcon, el sub balcon – ¸si-i povestea ➧ prietenei: auzi Merry, Locotenentul – dracu’ ¸stiecum ˆılcheam˘a!– pe dedesubt m-a ” cunoscut ¸sim-a salutat“. Bunica n-a ˆınv˘at¸at romˆana niciodat˘a¸sicred c-o amuz˘as˘a vorbeasc˘aaiurea. ➧ V˘amai amintit¸i de madama aia cu arsenicu’? Bovary? Ce mare dram˘acˆand˘ala i-a ridicat fustele pe malul lacului! Nu mi-am ˆın¸selat niciodat˘ab˘arbatul pˆan˘aacum.“ ” ➧❙ B˘aiatu’ a gemut de satisfact¸ie ¸si-a gˆandit: mi se breh˘ane,eu vreau s˘at¸i-o trag, indi- ferent cˆat¸i au fost ˆınaintea mea ¸sicˆat¸i or s˘amai fie dup˘a.
    [Show full text]
  • Full Schedule ILANIT 20Th-23Rd of February 2017
    Full Schedule ILANIT 20th-23rd of February 2017 ILANIT / FISEB Federation of all the Israel Societies for Experimental Biology (FISEB) איגוד האגודות הישראליות לביולוגיה ניסויית )אילנית( ILANIT/FISEB is a federation of 31 Israeli societies of experimental biology. ILANIT’s conference is held every three years in Eilat, with attendance by researchers and students. This conference, held in February 2017, is the culmination of the most exciting research performed in Israel in many disciplines. Board President Treasurer Secretary Prof. Karen B. Avraham Prof. Yaron Shav-Tal Prof. Eitan Yefenof (TEL AVIV UNIVERSITY) (BIU) (HUJI) Scientific Organizing Committee Conference President Conference Vice Conference Deputy Conference Vice Orna Amster-Choder President President President (HUJI) Maya Schuldiner (WIS) Angel Porgador (BGU) Eli Pikarsky (HUJI) 2 Last updated 15.02.2017 Scientific Advisory Committee Molecular and Structural Biology and Biochemistry Orna Elroy-Stein, Tel Aviv University (Chair) Ora Furman, Hebrew University of Jerusalem Shula Michaeli, Bar Ilan University Neurobiology and Endocrinology Yuval Dor, Hebrew University of Jerusalem (Chair) Yadin Dudai, Weizmann Institute of Science Assaf Rudich, Ben Gurion University of the Negev Genetics, Genomics, Epigenetics, Bioinformatics and Systems Biology Tzachi Pilpel, Weizmann Institute of Science (Chair) Ohad Birk, Ben Gurion University of the Negev Howard Cedar, Hebrew University of Jerusalem Yael Mandel, Technion – Israel Institute of Technology Medicine, Immunology and Cancer
    [Show full text]
  • Transformative Research at Ben-Gurion University of the Negev
    A DECADE OF TRANSFORMATIVE RESEARCH AT BEN-GURION UNIVERSITY OF THE NEGEV APRIL 2014 "Understanding the secrets of nature will be our greatest endeavor." David Ben-Gurion From the President 3 From the Vice-President and Dean for R&D 4 Leading The Way Ilse Katz Institute for Nanoscale Science and Technology 6 Homeland Security Institute 12 Cyber Security Initiative 16 Jacob Blaustein Institutes for Desert Research 20 Zuckerberg Institute for Water Research 21 French Associates Institute for Agriculture & Biotechnology of Drylands 24 The Swiss Institute for Dryland Environmental and Energy Research 27 Ben-Gurion National Solar Energy Center 29 The National Institute for Biotechnology in the Negev 32 Zlotowski Center for Neuroscience 38 The Edmond J. Safra Center for the Design and Engineering of Functional Biopolymers in the Negev 42 The Bengis Center for Entrepreneurship and Hi-Tech Management 44 Jacques Loeb Centre for the History and Philosophy of the Life Sciences 46 Center for the Study of Conversion and Inter-Religious Encounters 47 The Ben-Gurion Research Institute for the Study of Israel and Zionism 48 HEKSHERIM – the Research Institute for Jewish and Israeli Literature & Culture 49 Research Diversity Humanities Research at BGU 51 Medical Research at BGU 56 The BGU Energy Initiative 60 Robotics Research at BGU 63 The Research & Development Authority 66 Facilitating Innovation BGN Technologies 68 Advanced Technologies Park 70 Ten Years of Leadership in R&D 71 Produced by the Office of the Vice President & Dean for Research and Development in cooperation with the Scientific Publications Section and the Department of Publications and Media Relations.
    [Show full text]
  • Better Global Tools for Influenza
    11–12 June 2019 | Geneva, Switzerland BETTER GLOBAL TOOLS FOR INFLUENZA Technical consultation on product research & innovation for influenza prevention, control & treatment Prevent. Control. Prepare. 11–12 June 2019 | Geneva, Switzerland BETTER GLOBAL TOOLS FOR INFLUENZA Technical consultation on product research & innovation for influenza prevention, control & treatment WHO/WHE/IHM/IPR/2019.1 © World Health Organization 2019 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons. org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. Better global tools for influenza. Technical consultation on product research and innovation for influenza prevention, control and treatment, Geneva, Switzerland, 11-12 June 2019.
    [Show full text]
  • REPORT PLA2G6 Mutation Underlies Infantile Neuroaxonal Dystrophy
    CORE Metadata, citation and similar papers at core.ac.uk Provided by Elsevier - Publisher Connector REPORT PLA2G6 Mutation Underlies Infantile Neuroaxonal Dystrophy Shareef Khateeb,* Hagit Flusser,* Rivka Ofir, Ilan Shelef, Ginat Narkis, Gideon Vardi, Zamir Shorer, Rachel Levy, Aharon Galil, Khalil Elbedour, and Ohad S. Birk Infantile neuroaxonal dystrophy (INAD) is an autosomal recessive progressive neurodegenerative disease that presents within the first 2 years of life and culminates in death by age 10 years. Affected individuals from two unrelated Bedouin Israeli kindreds were studied. Brain imaging demonstrated diffuse cerebellar atrophy and abnormal iron deposition in the medial and lateral globus pallidum. Progressive white-matter disease and reduction of the N-acetyl aspartate:chro- mium ratio were evident on magnetic resonance spectroscopy, suggesting loss of myelination. The clinical and radiological diagnosis of INAD was verified by sural nerve biopsy. The disease gene was mapped to a 1.17-Mb locus on chromosome 22q13.1 (LOD score 4.7 at recombination fraction 0 for SNP rs139897), and an underlying mutation common to both affected families was identified in PLA2G6, the gene encoding phospholipase A2 group VI (cytosolic, calcium-indepen- dent). These findings highlight a role of phospholipase in neurodegenerative disorders. Infantile neuroaxonal dystrophy (INAD) (MIM 256600) is in INAD. PKAN usually has a late-infantile or juvenile age a neurodegenerative disease characterized by pathologic at onset, with patients typically surviving into their 3rd axonal swelling and spheroid bodies in the CNS.1 Onset decade.5 It is noteworthy that early-onset cases of PKAN is within the first 2 years of life, and the disease culminates and late-onset cases of INAD have been reported.5 Linkage in death by age 10 years.
    [Show full text]
  • 2020 Activities Summary
    2020 activities summary The European Scientific Working group on Influenza (ESWI) is a group of key scientific experts in influenza The European who have joined forces to reduce the burden of influenza in Europe: Scientific ■ Ted van Essen, Amersfoort, The Netherlands ■ Gülsah Gabriel, Heinrich-Pette-Institute, Leibniz Institute for Experimental Virology, Hamburg, Germany ■ Terho Heikkinen, University of Turku, Finland Working group ■ Susanne Herold, University of Giessen Lung Centre, Germany ■ George Kassianos, GP and National Immunisation Lead Royal College of General Practitioners, UK on Influenza ■ Edward C. Hutchinson, University of Glasgow, UK ■ Colin Russell, University of Amsterdam, The Netherlands ■ Peter Openshaw, Imperial College London, UK ■ Ab Osterhaus, Research Center for Emerging Infections and Zoonoses Hannover, Germany ■ Roman Prymula, Military Hospital of Hradec Kralove, Czech Republic ■ Sylvie van der Werf, Institut Pasteur, Paris, France ■ Marco Goeijenbier, Erasmus MC, Rotterdam, The Netherlands To realize its objective, ESWI has euregha European Regional and Local Health Authorities European Academy of Paediatrics established structural U.E.M.S - Section of Paediatrics - European Union of Medical Specialists partnerships with influenza stakeholder organisations: PGEU GPUE Pharmaceutical Group of the European Union Groupement Pharmaceutique de L’Union Européenne EUROPE CORONAVIRUS, FLU AND RSV COLLIDING IN THE FALL In the middle of the COVID-19 pandemic and when the world was dealing with the unrelenting daily spread of the novel coronavirus ESWI wanted to look further down the road. In June 2020 already we wanted to warn the world that when flu season comes, there is a possibility that the world would be dealing with two respiratory viruses at the same time – flu and COVID-19.
    [Show full text]
  • Research at the NIBN
    Research at the NIBN Engineering affinity scaffolds for cancer imaging and therapy Itay Cohen and Dr. Niv Papo Research at the NIBN Ben-Gurion UNIVERSITY OF THE NEGEV Contents NIBN Overview 5 Cancer Research Group 6 Dr. Eyal Arbely 7 Dr. Roi Gazit 8 Dr. Dan Levy 9 Dr. Niv Papo 10 Prof. Angel Porgador 11 Dr. Barak Rotblat 12 Prof. Varda Shoshan-Barmatz 13 Autoimmune and Metabolic Diseases Group 14 Prof. Amir Aharoni 15 Prof. Angel Porgador 16 Prof. Assaf Rudich 17 Prof. Orian Shirihai 18 Neurodegenerative Diseases Group 19 Dr. Anat Ben-Zvi 20 Prof. Alon Monsonego 21 Prof. Israel Sekler 22 Prof. Varda Shoshan-Barmatz 23 Infectious Diseases Group 24 Dr. Natalie Elia 25 Dr. Eyal Gur 26 Dr. Tomer Hertz 27 Prof. Michael M. Meijler 28 Human Genetic Disorders Group 29 Prof. Ohad Birk 30 Prof. Ruti Parvari 31 Dr. Esti Yeger-Lotem 32 Applied Biotechnology Group 33 Prof. Ohad Medalia 34 Prof. Amir Sagi 35 Dr. Raz Zarivach 36 Dr. Stas Engel 37 Infra-Structure Supporting Group 38 Bioinformatics Core Facility 39 Crystallography Unit 40 Genetics Unit 41 Cytometry, Proteomic and Microscopy Unit 42 Dr. Roee Atlas 43 NIBN Overview The National Institute for Biotechnology in the Negev Using these approaches, NIBN has already succeeded (NIBN) Ltd. is the first, self-organized, independent to generate commercial outlets in the fields of drug scientific research and development (R&D) body in targets for cancer therapy and infectious diseases, Israel. It has been established through a tri-lateral anti-inflammatory drugs as well as major advances agreement between the government of Israel, in aquaculture technology.
    [Show full text]
  • Minimal Transmission in an Influenza a (H3N2) Human Challenge-Transmission Model With
    medRxiv preprint doi: https://doi.org/10.1101/2019.12.13.19014381; this version posted December 15, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . Title Page Title Minimal transmission in an influenza A (H3N2) human challenge-transmission model with exposure events in a controlled environment Jonathan S. Nguyen-Van-Tama, Ben Killingleya, Joanne Enstonea, Michael Hewitta, Jovan Pantelicb,1, Michael Granthamb,2, P. Jacob Bueno de Mesquitab, Robert Lambkin-Williamsc, Anthony Gilbertc, Alexander Mannc, John Fornic,3, Catherine J. Noakesd, Min Z. Levinee, LaShondra Bermane, Stephen Lindstrome, Simon Cauchemezf,4, Werner Bischoffg, Raymond Tellierh, and Donald K. Miltonb, for the EMIT Consortium5. aHealth Protection and Influenza Research Group, Division of Epidemiology and Public Heath, University of Nottingham School of Medicine, Nottingham, UK, NG7 2RD; bUniversity of Maryland School of Public Health, Maryland Institute for Applied Environmental Health, College Park, MD, USA, 20742; chVIVO London, UK, E1 2AX; dUniversity of Leeds School of Civil Engineering, Leeds, UK, LS2 9DY; eCenters for Disease Control and Prevention, Influenza Division, Atlanta, GA, 30333; fImperial College London, MRC Centre for Outbreak Analysis and Modelling, Department of Infectious Disease Epidemiology, London, UK, SW7 2AZ; gWake Forest School of Medicine, Winston-Salem, NC, 27101; hUniversity of Calgary, Cumming School of Medicine, Department of Pathology and Laboratory Medicine, Calgary, Alberta, CA, AB T2N 4N1 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
    [Show full text]